Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 11 Pancreatic Neoplasms 3 Carcinoma, Hepatocellular 2 Uterine Cervical Neoplasms 1 Rectal Neoplasms 1 Malignant Neoplasms of Digestive Organs 1 Head and Neck Neoplasms 1 Fruquintinib 1 For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method 1 Esophageal Squamous Cell Carcinoma 1 Esophageal 1 Colonic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Biliary Tract Neoplasms 1 Apatinib Combined 1 Advanced Pancreatic Cancer 1

Interventions

raltitrexed 1 potassium oxonate 1 gimeracil 1 Tegafur 1 S 1 (combination) 1 Irinotecan 1 HMPL-013 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Fruquintinib × gimeracil × Clear all

NCT06427005 2025-01-22

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

West China Hospital

Phase 2 Recruiting

Fruquintinib

Data powered by HemOnc (CC BY 4.0) Colophon ⚡